Immunization against angiotensin II can reduce ambulatory blood pressure
This article has no abstract so we have provided the first paragraph of the full text.
Hypertension can be adequately controlled with pharmacological treatment; however, low adherence to medication means that many patients with hypertension do not achieve such control. Treatment of hypertension by immunization against angiotensin II, involving for example a few injections per year, could markedly improve patient compliance. In a multicenter, double-blind, placebo-controlled phase IIa trial, Tissot et al. examined the safety and efficacy of CYT006-AngQb—a vaccine comprising angiotensin II conjugated to recombinant virus-like particles—in 72 patients with mild to moderate hypertension.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
